Development of new indicators for the launch of a Japanese version of the NIH (1) : An overview and future prospects of pharmaceutical industry based on new indicators

Abstract

For the sake of providing evidences that contribute to policy making or strategy planning in a Japanese version of the NIH and pharmaceutical companies, we tried an overview and future prospects of pharmaceutical industry based on new indicators. We focused on the R&D pipelines of each pharmaceutical company. The results show that the R&D capacity of each country in the current stage and in future can be measured, by structuring the pipeline data in each R&D step, comparing the number of marketed pharmaceuticals and so on. Consequently, the competitive advantage of US and the idiosyncrasy of Japan have been thrown into sharp relief.